gmp
gmp

Find Drugs for Pulmonary/Respiratory Diseases in Preclinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Recombinant human plasma gelsolin

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 04, 2020

            Details:

            The compelling data from this NIH sponsored study show the potential of gelsolin to not only improve survival, but to diminish lung injury caused by virulent pneumonia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Exebacase

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CF-370

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding August 25, 2020

            Details:

            First stage of the agreement will fund in vitro activity of ContraFect’s next product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa, and amurin peptides, against bacterial specimens obtained from CF patients at different stages of disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MORF-720

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MORF-720

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: $120.0 million Upfront Cash: $100.0 million

            Deal Type: Licensing Agreement August 25, 2020

            Details:

            AbbVie has exercised a license option under the companies’ research and development collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ASX-100

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ASX-100

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Orange Grove Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding August 25, 2020

            Details:

            ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials of the drug.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Larazotide Acetate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INN-202

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 28, 2020

            Details:

            U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent for Use of Tight Junction Antagonists in the Treatment of Acute Lung Injury and Acute Respiratory Distress, relating to its proprietary investigational agent, larazotide.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MRG-229

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MRG-229

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2020

            Details:

            MRG-229 has demonstrated mechanistic biomarker regulation and antifibrotic activity in vitro using human model systems.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sinapultide

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co

            Deal Size: $20.2 million Upfront Cash: Undisclosed

            Deal Type: Public Offering May 22, 2020

            Details:

            Windtree intends to use the net proceeds from this offering to advance the study of KL4 surfactant to treat COVID-19 related lung injury; istaroxime acute heart failure phase 2b start-up activities;clinical development of AEROSURF;pre-clinical studies of SERCA2a activators.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MBT2

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 01, 2020

            Details:

            CohBar’s poster will contain data on a family of novel analogs of a peptide encoded in mitochondrial DNA, demonstrating beneficial effects in mouse models of Idiopathic Pulmonary Fibrosis (IPF).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MBT2

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 14, 2020

            Details:

            The presentation highlights potential of MBT2 to Inhibit Fibrogenesis in Cultured Human Lung Cells and its efficacy in Mouse Models of Idiopathic Pulmonary Fibrosis (IPF).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SVX-24

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $110.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing March 26, 2020

            Details:

            SutroVax has generated preclinical proof of concept versus the standard of care vaccines and intends to advance SVX-XP into the clinic as a future successor to SVX-24.

            PharmaCompass